COO Q2 Deep Dive: Margin Pressures and Product Shifts Drive Cautious Outlook

Medical device company CooperCompanies (NASDAQ:COO) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 5.7% year on year to $1.06 billion. On the other hand, next quarter’s revenue guidance of $1.06 billion was less impressive, coming in 2.8% below analysts’ estimates. Its non-GAAP profit of $1.10 per share was 3% above analysts’ consensus estimates.

Is now the time to buy COO? Find out in our full research report (it’s free).

StockStory’s Take

CooperCompanies’ second quarter results were met with a negative market reaction, as investors responded to both the company’s execution and shifting demand dynamics in the contact lens segment. Management attributed the quarter’s performance to lower-than-expected sales of its Clarity lenses, particularly in Asia Pacific, and ongoing weakness in the region’s e-commerce channels. CEO Al White highlighted that “the clarity decline was led by a noticeable drop in Asia Pac and a slowdown in the Americas and EMEA,” while also noting double-digit growth in premium MyDay lenses. The company’s ability to maintain profitability amid these headwinds was supported by operational discipline and continued demand for its premium offerings.

Looking ahead, management’s guidance reflects uncertainty around the pace at which MyDay fitting activity will convert into revenue and continued pressure in lower-margin channels. CEO Al White explained that while MyDay’s global momentum is encouraging, the transition from fitting sets and trial lenses to actual orders makes near-term forecasting challenging: “A significant portion of the activity is tied to fits and trial lenses, which typically take a couple quarters to convert into revenue.” The company also expects ongoing tariff headwinds and slow recovery in the fertility business, but remains confident about regaining market share through new product launches and contract wins, particularly for MyDay and MiSight.

Key Insights from Management’s Remarks

Management pointed to shifting customer preferences, recent operational changes, and evolving market conditions as key factors shaping the quarter’s results and forward-looking guidance.

• Clarity softness in Asia Pacific: Management noted a sharper-than-expected decline in Clarity lens demand, especially in Asia Pacific, as customers shifted focus toward MyDay fittings, impacting immediate revenue but expected to benefit future quarters.
• MyDay capacity expansion: The resolution of previous production constraints allowed CooperCompanies to accelerate MyDay fitting set rollouts, leading to double-digit growth for the premium product family and renewed private label contract activity.
• Pure play e-commerce weakness: The company saw continued softness in Asia Pacific’s e-commerce channel, especially in China, with lower-margin sales declining due to competitive pricing from rivals. Management indicated this trend had a minimal impact on overall profitability but weighed on top-line growth.
• Fertility market headwinds: CooperSurgical’s fertility business faced delayed capital purchases and softer procedure volumes in Asia Pacific, though management remains optimistic about long-term demand fundamentals such as delayed childbirth and increased access to treatment.
• Margin and efficiency initiatives: The company is implementing productivity and efficiency measures, including IT upgrades and organizational restructuring, aiming to offset margin pressures from tariffs and product mix and to improve free cash flow conversion in future periods.

Drivers of Future Performance

CooperCompanies’ outlook is shaped by the ongoing MyDay transition, regional market headwinds, and a focus on operating discipline to support margin stability.

• MyDay ramp and market share: Management expects MyDay’s expanded availability and new private label contracts to drive market share gains and revenue growth, but acknowledges that the timing of fitting activity translating into sales remains uncertain and could span several quarters.
• Tariff and margin headwinds: The company is implementing tariff mitigation strategies, but gross margins will face near-term pressure from product mix shifts and external cost factors, with offsetting actions planned through cost controls and organizational restructuring.
• Fertility recovery and product launches: CooperSurgical’s growth prospects hinge on a rebound in fertility procedure volumes, particularly in Asia Pacific, and successful commercialization of new products like MiSight in Japan and MyDay’s expanded offerings in Europe and Asia.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be closely watching (1) the pace at which MyDay fitting activity converts into revenue and whether recent contract wins accelerate share gains, (2) progress on margin stabilization amid tariff and product mix headwinds, and (3) early indicators of recovery in the fertility segment, especially in Asia Pacific. We will also track the effectiveness of cost control and restructuring initiatives on free cash flow.

CooperCompanies currently trades at $64.11, down from $74.12 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.